Skip to main content

Table 1 Univariate analysis of factors associated with bleeding events during CA with uninterrupted periprocedural edoxaban

From: Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study

Factors Univariate
OR (95% CI)
p-value
Sex
 Female vs male 1.182 (0.397–3.519) 0.7633
Age, years
 65–74 vs < 65 2.604 (0.682–9.949) 0.1617
  ≥ 75 vs < 65 3.835 (0.839–17.542) 0.0831
AF type
 Non-paroxysmal vs paroxysmal 2.144 (0.752–6.116) 0.1539
CA surgical type
 Radiofrequency vs cryoballoon 1.948 (0.433–8.765) 0.3848
CHADS2 score
  ≥ 2 vs < 2 2.194 (0.781–6.162) 0.1360
HAS-BLED score
  ≥ 3 vs < 3 9.478 (2.363–38.014) 0.0015
Renal function (CrCL), mL/min
  ≤ 50 vs > 50 10.594 (3.645–30.790) < 0.0001
Edoxaban dose the day before CA, mg
 30 vs 60 3.492 (1.175–10.378) 0.0245
Time from CA termination to restart of edoxaban administration on the day of CA, hours
  ≥ 3 and < 6 vs < 3 1.159 (0.127–10.570) 0.8956
  ≥ 6 vs < 3 2.124 (0.261–17.314) 0.4817
Plasma concentration of edoxaban before CA (ng/mL) 1.005 (0.974–1.038) 0.7331
Perioperative heparin dose (unit) 1.003 (0.993–1.013) 0.5387
Maximum ACT during CA (s) 1.011 (0.951–1.075) 0.7222
  1. For each factor, the category to the right is the reference. The final 3 items were considered continuous variables. Factors found to be significant in the univariate analysis were subsequently entered into multivariate analysis
  2. ACT activated clotting time; AF atrial fibrillation; CA catheter ablation; CI confidence interval; CrCL creatinine clearance; OR odds ratio